Transgene is designing and developing next-generation immunotherapeutics against cancer
April 19, 2023 | 12:00 PM ETLIVE Q&A
KOL EVENT
TG4050: Individualized cancer Vaccine
in HPV-Negative Head & Neck Cancers
TG4050
First positive data
from Phase I clinical trials
Innovative technologies
Push the boundaries of immunotherapy
Transgene combines cutting-edge technologies, a multidisciplinary team and a prestigious international network.
Discover our two therapeutic approaches
Discover our technologies
One patient, one cancer, one vaccine
With myvac®, Transgene enters the field of individualized immunotherapies with a unique virus-based immunotherapy platform.
myvac® video Discover myvac®
A new generation of products
These innovative multifunctional OVs are able to modulate the tumor micro-environment to better attack cancer.
Discover invir.IO®
TG4001
A therapeutic vaccine in Phase II
TG4001 targets HPV-induced anogenital cancers.
More information
Transgene presented data confirming the potential of the Invir.IO® oncolytic viruses administered intravenously 
Transgene in a nutshell
ESMO 2022
Donwload Press release (PDF)
TG6002 en images
Press releases
- May 26, 2023 - Transgene to Present Data on its Two Therapeutic Cancer Vaccins at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
- May 25, 2023 - Transgene and BioInvent report positive Phase Ia data on oncolytic virus BT-001 in solid tumors
- May 10, 2023 - Transgene provides business update and Q1 2023 financial position
- May 10, 2023 - Transgene – First Patient Dosed in Phase I Trial Evaluating TG6050, a Novel IL-12-Armed Oncolytic Virus Administrated Intravenously, in Non-Small Cell Lung Cancer
Last publications
- April 16, 2023 - TG6050 an oncolytic vaccinia virus armed with interleukin 12 and anti-CTLA4 antibody induces TME remodeling and strong anti-tumoral responses
- September 11, 2022 - Updated data of biodistribution and activity of oncolytic virus TG6002 after intravenous administration in patients with advanced gastrointestinal carcinomas
- April 12, 2022 - Phase I trials of personalized cancer vaccine TG4050 in surgically treated high-risk head and neck squamous cell carcinoma (HNSCC) and relapsing ovarian cancer (OvC) patients
- January 19, 2022 - Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject “cold” tumors
Latest webcasts
- May 5, 2023 - New Leadership Structure to Accelerate the Development of its Innovative Immunotherapy Portfolio
- March 16, 2023 - 2022 Full-year results and business update
- September 27, 2022 - Transgene R&D Day (Paris, France)
